- Conditions
- Systemic Sclerosis
- Interventions
- Belimumab, Mycophenolate Mofetil, Placebo Infusion
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 47
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
- Interventions
- German manufactured UVA1 emitting light system
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 10 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 513 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- MTX-474, Placebo
- Biological · Other
- Lead sponsor
- Mediar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Loma Linda, California + 19 more
- Conditions
- Systemic Sclerosis, Scleroderma, Diffuse Systemic Sclerosis, Diffuse Scleroderma, Diffuse Cutaneous Systemic Sclerosis, Diffuse Cutaneous Scleroderma, Progressive Systemic Sclerosis, Progressive Scleroderma, Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma;Progressive, Systemic Sclerosis, Diffuse, Systemic; Sclerosis, Progressive, Scleroderma of Lung, Scleroderma With Pulmonary Involvement, Systemic Sclerosis Pulmonary, Systemic Sclerosis With Lung Involvement, Interstitial Lung Disease, Pulmonary Fibrosis Interstitial
- Interventions
- Ixazomib
- Drug
- Lead sponsor
- Michael M. Pham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Systemic Sclerosis
- Interventions
- SAR156597, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
- Conditions
- Morphea, Scleroderma, Localized, Scleroderma
- Interventions
- FCX-013, veledimex
- Genetic · Drug
- Lead sponsor
- Castle Creek Biosciences, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Mycophenolate Mofetil
- Drug
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
- Interventions
- Brentuximab Vedotin, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Tofacitinib, Placebo Oral Tablet
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Pittsburgh, Pennsylvania
- Conditions
- System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Belumosudil (KD025), Placebo
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Belumosudil
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- TEPEZZA, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule
- Drug · Other
- Lead sponsor
- Corbus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 27
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more
- Conditions
- Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
- Interventions
- KYV-101, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- David Porter
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
- Interventions
- HZN-825
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more
- Conditions
- Scleroderma, Systemic Sclerosis
- Interventions
- Divalproex sodium
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Female only
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
- Interventions
- KYV-101, Standard lymphodepletion regimen
- Biological · Drug
- Lead sponsor
- Kyverna Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Great Neck, New York
- Conditions
- Systemic Scleroderma, Diffuse Cutaneous Scleroderma
- Interventions
- Spatial-frequency domain imaging (SFDI)
- Other
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
- Interventions
- Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI), Optical Coherence Tomography (OCT), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC)
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Interventions
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Biological · Drug
- Lead sponsor
- Century Therapeutics, Inc.
- Industry
- Eligibility
- 17 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
- Conditions
- Systemic Sclerosis
- Interventions
- Belimumab, Rituximab, Placebo Subcutaneous Injection, Placebo Infusion, MMF
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label)
- Combination Product · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more